Houston Pharmacy Centric Compounding Recalls Glutathione, Myer's Cocktail and Tri-Immune Boost Nationwide Over Elevated Endotoxin

A compounding pharmacy that supplies injectable wellness drips has issued a fresh nationwide recall tied to a recurring safety failure in this product category. On September 9, 2026, Centric Compounding LLC of Houston, Texas announced a voluntary recall, to the consumer level, of six lots of injectable products after the products were compounded with a glutathione active ingredient found to contain elevated bacterial endotoxin levels. The U.S. Food and Drug Administration posted the recall notice on September 13, 2026. Because these products are commonly prescribed and shipped to patients through telehealth wellness clinics, longevity practices and IV-therapy providers, the recall is relevant to anyone who received one of the affected lots.

What was recalled

According to the FDA recall notice, Centric Compounding is recalling six lots across three injectable products, all supplied in 30 mL multidose vials. The affected products and lots are:

• Glutathione 200 mg/mL: lots 062326:B (beyond-use date 8/7/26), 070826:A (8/22/26) and 072726:D (9/25/26).
• Myer's Cocktail: lots 070226:D (beyond-use date 8/16/26) and 072126:A (9/4/26).
• Tri-Immune Boost: lot 071626:B (beyond-use date 8/30/26).

The recall is described as voluntary and nationwide, conducted to the consumer level, meaning the pharmacy is seeking return of product already dispensed to individual patients rather than only pulling stock from distributors. The notice states the products were distributed nationwide to patients through home delivery and to prescriber offices. Myer's Cocktail and Tri-Immune Boost are combination injectables marketed for immune support and general wellness, so the recall reaches beyond glutathione alone into the broader IV-drip category.

Why it was recalled

The stated reason is that the products were compounded using a glutathione API that was found to contain elevated endotoxin levels. Endotoxins are components of certain bacteria that can trigger a strong inflammatory response when introduced into the bloodstream, even when no live organisms are present. Per the FDA notice, there is a reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death. That is the stated risk profile for elevated-endotoxin injectables generally, as described in the recall; it is not a claim that every exposed patient will experience harm. The recall notice attributes the problem to the glutathione active ingredient and does not identify the ingredient's supplier.

Reported adverse events

The pharmacy says that, to date, it has received nine reports of adverse events associated with the recalled products. The reported effects listed in the notice include fever, chills, chest pain, nausea or vomiting, headache and malaise. These are reports received by the pharmacy rather than confirmed, adjudicated cases, and the notice states that no deaths have been reported. The notice does not provide the severity of individual cases or confirm a causal link for every report.

A cluster of endotoxin recalls in compounded injectables

The Centric recall does not stand alone. It follows a run of 2026 recalls by Texas compounding pharmacies over elevated endotoxin in glutathione injectables, including Victory Medical Center Pharmacy of Austin and Optimal Balance Pharmacy of Houston. See our earlier coverage of the Victory Medical Center recall for detail on that action.

On August 27, 2026, the FDA issued a broader reminder that compounders should not use dietary supplement grade glutathione to make injectable drugs. In that communication the agency stated that ingredients labeled for dietary supplement use may contain impurities and contaminants, including endotoxins, that may be harmful when administered as an injectable drug. The FDA said it was aware of at least 30 patients who experienced adverse events across multiple compounding pharmacies, and it pointed to a specific glutathione lot (Lot #229536 from Medisca Inc. of Plattsburgh, New York) that was associated with recalls by two Texas pharmacies. The agency noted this is not a new concern, having previously warned about endotoxin in compounded glutathione in 2019. The Centric notice does not state whether its glutathione API came from that lot or supplier, so any link to the earlier cluster is not established by the recall notice itself.

Why this matters for telehealth patients

Injectable glutathione and combination drips like Myer's Cocktail and Tri-Immune Boost are frequently marketed through wellness, longevity and IV-therapy channels, prescribed via telehealth and shipped directly to patients. That distribution model means an affected patient may not have a local pharmacist to consult and may be several steps removed from the compounding pharmacy that prepared the product. A consumer-level recall for a mailed injectable therefore depends on the pharmacy reaching each recipient. Centric says it is notifying its distributors and customers by email and is providing phone and email contacts for the recall.

What affected patients can do

This is general information, not medical advice. If you have one of these injectable products, these steps follow the guidance in the recall notice and standard FDA reporting channels:

• Check whether your vial is Centric Compounding Glutathione 200 mg/mL, Myer's Cocktail or Tri-Immune Boost from one of the six recalled lots listed above, and stop using it if so.
• Contact Centric Compounding at 833-777-6664 or info@centriccompounding.com (Monday through Friday, 9am to 5pm CST) with questions about the recall and return of affected product.
• If you have used an affected lot and feel unwell, contact your prescribing clinician or seek medical care; the notice describes potential reactions ranging from fever and chills to more serious events.
• Report any adverse event to the FDA's MedWatch program online or by calling 1-800-332-1088.
• Ask any telehealth or compounding provider how they source and test injectable products, including whether each batch and its active ingredients are tested for bacterial endotoxin.